The SPRINT study
Research type
Research Study
Full title
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
IRAS ID
326983
Contact name
Dana Dawson
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Cardiotoxicity is heart damage that arises from certain drugs, such as cancer treatment. Cardiotoxicity develops in approximately 10% of patients with breast cancer who are treated with a certain type of chemotherapy, known as anthracyclines. It has been suggested that certain drugs, knowns as sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. In this study, we want to see if taking a SGLT2 inhibitor, a medicine called dapagliflozin, daily during chemotherapy treatment can reduce the rate of cardiotoxicity.
REC name
North of Scotland Research Ethics Committee 1
REC reference
24/NS/0003
Date of REC Opinion
28 Jan 2024
REC opinion
Favourable Opinion